The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Acerta Pharma; Janssen Research & Development; Merck Sharp & Dohme; Pharmacyclics; Seagen
Acalabrutinib combined with PI3Kδ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.
 
Paul M. Barr
Consulting or Advisory Role - Abbvie; Celgene; Genentech; Infinity Pharmaceuticals; Janssen; Novartis; Pharmacyclics; Seagen
Research Funding - Pharmacyclics (Inst)
 
Stephen Douglas Smith
No Relationships to Disclose
 
Mark J. Roschewski
No Relationships to Disclose
 
Susan Mary O'Brien
Employment - University of California, Irvine
Honoraria - Abbvie; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Eisai; Gilead Sciences; GlaxoSmithKline; Janssen; Loxo; Pfizer; Pharmacyclics; Sunesis Pharmaceuticals; TG Therapeutics; Vaniam Group
Consulting or Advisory Role - Abbvie/Genentech; Alexion Pharmaceuticals; Amgen; Amgen Astellas BioPharma; Aptose Biosciences; Celgene; CLL Global Research Foundation; Eisai; GlaxoSmithKline; Janssen Oncology; Loxo; Pharmacyclics; Sunesis Pharmaceuticals; Vaniam Group
Research Funding - Acerta Pharma; Gilead Sciences; Pfizer; Pharmacyclics; ProNAI; Regeneron; TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Janssen Oncology; Regeneron
 
Jeff Porter Sharman
Leadership - US Oncology
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Pharmacyclics; TG Therapeutics
Speakers' Bureau - Gilead Sciences
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst)
Expert Testimony - Gilead Sciences
 
Jason M. Melear
No Relationships to Disclose
 
Ahmed M. Hamdy
Employment - Acerta Pharma
Stock and Other Ownership Interests - Acerta Pharma
 
Raquel Izumi
Employment - Acerta Pharma
Stock and Other Ownership Interests - Acerta Pharma
Consulting or Advisory Role - Trigemina
Patents, Royalties, Other Intellectual Property - Patents pending for Acerta Pharma
 
J. Greg Slatter
Employment - Acerta Pharma
Stock and Other Ownership Interests - Acerta Pharma
 
Nataliya Chernyukhin
Employment - Acerta Pharma
Stock and Other Ownership Interests - AstraZeneca
 
Elena Bibikova
Employment - Acerta Pharma
Stock and Other Ownership Interests - Acerta pharma; AstraZeneca
 
Ming Yin
Employment - Acerta Pharma
Stock and Other Ownership Interests - AstraZeneca
 
Tianling Chen
Employment - Acerta Pharma
Stock and Other Ownership Interests - AstraZeneca; Merck
 
Stephen Edward Forbes Spurgeon
Honoraria - Gilead Sciences; Pharmacyclics
Consulting or Advisory Role - Gilead Sciences; Pharmacyclics
Research Funding - Acerta Pharma (Inst); Genentech (Inst); Gilead Sciences (Inst); Janssen (Inst)